XAGE-1b nonapeptide and application thereof

A technology of xage-1b, 1.xage-1b, applied in the field of tumor-associated antigen XAGE-1b short peptide and its application, can solve the problems of further improvement of experimental data, unsatisfactory results, poor specificity, etc., and achieve The effect of good clinical translation and practical application prospects

Inactive Publication Date: 2019-07-16
广州美萨生物科技有限公司
View PDF4 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the technical scheme disclosed by CN102428102A, an attempt is made to intercept a part of the XAGE-1b antigen to induce humoral immunity or cellular immunity to the tumor, but the result is not satisfactory, and the length of the polypeptide is still not shorter than 16AA
Short peptides may also have the problem of poor specificity. How to obtain short peptides with good specificity and good immunogenicity is a very challenging task
[0011] CN106243213A, CN106279391A and CN106279392A disclose a series of XAGE-1b short peptides, which illustrate that it is feasible for short peptides to induce specific immune responses, but experimental data show that it needs further improvement

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • XAGE-1b nonapeptide and application thereof
  • XAGE-1b nonapeptide and application thereof
  • XAGE-1b nonapeptide and application thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0027] XAGE-1b short peptide, its sequence is GSRQKKIRI.

[0028]Application of XAGE-1b short peptide in inducing and preparing tumor-specific cytotoxic T cell clone, wherein the sequence of XAGE-1b short peptide is GSRQKKIRI.

[0029] A method for inducing tumor-specific cytotoxic T cells. The XAGE-1b short peptide whose sequence is GSRQKKIRI is presented by dendritic cells and co-cultured with CD8+ T cells, and induced and screened to obtain tumor-specific cytotoxic T cells.

[0030] A tumor polypeptide vaccine is composed of active antigen components and adjuvants, and the active antigen components are XAGE-1b short peptides whose sequence is GSRQKKIRI.

[0031] A DC vaccine for tumor treatment, which is mainly obtained by loading the XAGE-1b short peptide with the sequence GSRQKKIRI and dendritic cells.

[0032] The application of the XAGE-1b short peptide in the preparation of a non-small cell lung cancer diagnostic kit, wherein the sequence of the XAGE-1b short peptide ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention discloses a XAGE-1b nonapeptide and an application thereof. A sequence of the XAGE-1b short peptide is GSRQKKIRI. CTLs induced by the XAGE-1b antigen peptide do not produce an immune response to testicular cells and only kill tumor cells. The induced CTL clones have a good tumor cell specific killing effect. At the same time, in process of establishing the CTLs, inventors find that the sieved XAGE-1b antigen peptide has appropriate affinity with HLA on DC cells and can effectively stimulate and induce the production of the specific CTLs, indicating that the XAGE-1b antigen peptide has a good potential as a polypeptide vaccine and a DC vaccine. By cloning a XAGE-1b antigen peptide-specific TCR gene, constructing a viral vector and transducing peripheral circulating CD8+ T cells, TCR gene-modified T cell (TCR-T) clones are obtained, also have the tumor cell specific killing effect similar to that of parental CTLs, and have good clinical transformation and practicalapplication prospects.

Description

technical field [0001] The invention relates to tumor-associated antigen peptides and applications thereof, in particular to tumor-associated antigen XAGE-1b short peptides and applications thereof. Background technique [0002] As we all know, T cell adoptive therapy for tumors is currently the most eye-catching technology, especially the application of receptor-engineered T cells (TCR-T) is becoming an exciting cancer treatment method, and it also has therapeutic effects on viral infections and autoimmune diseases. Wide application prospects. [0003] The human immune surveillance system plays an important role in the process of resisting tumor growth. The immune surveillance system achieves the purpose of inhibiting tumor growth by coordinating various types of immune cells, among which cytotoxic T cells (cytotoxic Tlymphocytes, CTLs) play an extremely important role and are the most important. Key killer effector cells. tumor antigen-specific CD8 + T cells can specifi...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): C07K14/47C12N5/0783C12N5/0784A61K39/00A61P35/00G01N33/68G01N33/574
CPCA61K39/0011A61K2039/5154A61P35/00C07K14/4748C12N5/0638C12N2502/1121G01N33/57423G01N33/57484G01N33/68G01N2333/47
Inventor 张蓓
Owner 广州美萨生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products